Fig. 1

Kaplan–Meier curves for the time to first emetic episode (vomiting or nausea) and first use of rescue medication during the first 288 h following administration of chemotherapeutic drugs. 5-HT₃RA [ramosetron (0.1 mg/body, orally) or granisetron (3 mg/body, intravenously)] (solid line), or metoclopramide (5 mg/body, orally) (dashed line) was administered once per day from Day 1 (before initiation of azacitidine) to Day 7 (HR for 5-HT₃RA vs. metoclopramide, 0.127; 95% CI, 0.045–0.358; p < 0.001, Cox proportional hazard regression analysis). 5-HT₃RA, 5-HT₃ receptor antagonist